Condition: Mild Cognitive Impairment · Dementia · Subjective Cognitive Decline (SCD) · Sponsor: Ewha Womans University Mokdong Hospital
The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to evaluate the impact of these new therapies and diagnostic techniques in clinical practice.
This description comes directly from the study's public registry record.
Geon-ha Kim · 82-2-587-7462 · geonha@ewha.ac.kr
Always discuss trial participation with your own doctor first.
| Gachon University Gil medical Center | Incheon, South Korea | Recruiting |
| Inha University Hospital | Incheon, South Korea | Recruiting |
| Ewha Womans University Mokdong Hospital | Seoul, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06889818